You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 1, 2026

List of Excipients in Branded Drug BUSPIRONE


✉ Email this page to a colleague

« Back to Dashboard


Generic Drugs Containing BUSPIRONE

Excipient Strategy and Commercial Opportunities for Buspirone

Last updated: March 8, 2026

What is the role of excipients in buspirone formulations?

Excipients in buspirone formulations serve multiple functions: they enhance drug stability, improve bioavailability, facilitate manufacturing, and influence patient adherence. Common excipients include binders, fillers, disintegrants, lubricants, and coatings.

How do excipients impact buspirone's bioavailability and stability?

Buspirone exhibits moderate biopharmaceutical challenges due to its low solubility and extensive first-pass metabolism. Appropriate excipient choices can optimize dissolution rates and absorption.

  • Solubilizers: Use of surfactants like sodium lauryl sulfate enhances solubility.
  • Protective Agents: Antioxidants (e.g., ascorbic acid) guard against oxidative degradation.
  • pH Adjusters: Acidic or buffering agents stabilize the pH, influencing stability and absorption.

What are current formulation trends for buspirone?

Recent formulations focus on improving bioavailability and patient compliance:

  • Immediate-release tablets: Standard formulation, relies on excipients for fast dissolution.
  • Extended-release formulations: Use of matrix systems with polymers like hydroxypropyl methylcellulose (HPMC) extends release.
  • Oral disintegrating tablets (ODTs): Disintegrants like sodium starch glycolate facilitate rapid melting without water.

What excipient strategies are viable for new buspirone formulations?

Innovative approaches include:

  • Nanoparticle-based excipients: Enhance solubility and absorption.
  • Premium polymers: Such as polyvinylpyrrolidone (PVP) for controlled release.
  • Taste-masking agents: Essential for ODTs to address bitter taste.

What commercial opportunities exist with excipient innovation?

Developing patent-protected formulations with novel excipients can:

  • Differentiation: Offer faster onset or reduced side effects.
  • Market expansion: Address unmet needs in pediatric, geriatric, or depot formulations.
  • Partnerships: Collaborate with excipient suppliers for co-development.

How do excipient choices influence regulatory approval?

Regulators demand:

  • Evidence of excipient safety (Generally Recognized As Safe - GRAS).
  • Compatibility data between excipients and active pharmaceutical ingredient (API).
  • Proper documentation for manufacturing process changes.

Leveraging known excipients with established safety profiles accelerates approval.

What are the key considerations in excipient sourcing and supply chain management?

  • Quality assurance: Sourced from validated suppliers.
  • Supply stability: Critical for continuous manufacturing.
  • Cost considerations: Balance between premium excipients and budget constraints.
  • Regulatory compliance: Documentation for each excipient variant.

What are the patent landscape implications?

Excipients can serve as patentable novel delivery systems if combined innovatively. Patent protections can extend market exclusivity, especially with formulations targeting specific patient populations.


Key Takeaways

  • Excipient choices influence buspirone’s bioavailability, stability, and patient compliance.
  • Strategies include solubilization, controlled-release matrix design, and taste-masking.
  • Innovation in excipients offers differentiation, market expansion, and potential patent advantages.
  • Regulatory pathways favor excipients with established safety profiles.
  • Supply chain management ensures formulation success and regulatory compliance.

FAQs

1. Can excipient selection affect buspirone's efficacy?
Yes. Excipients impact drug dissolution and absorption, directly influencing therapeutic effectiveness.

2. Are there any excipients to avoid in buspirone formulations?
Excipients with known incompatibilities or safety concerns, such as certain dyes or preservatives, should be avoided unless validated.

3. What excipient innovations could improve buspirone’s patient adherence?
Taste-masking agents and formulations like orally disintegrating tablets enhance compliance, especially in pediatric or elderly patients.

4. How does excipient choice influence manufacturing costs?
Premium excipients or complex delivery systems increase costs but may provide market differentiation and licensing opportunities.

5. What regulatory challenges exist with new excipient formulations?
Demonstrating excipient compatibility, safety, and manufacturing consistency are key hurdles. Known excipients with established profiles ease approval.


References

  1. DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20-33.
  2. United States Food and Drug Administration (FDA). (2020). Guidance for Industry: Excipients in Approved Drug and Biological Products.
  3. European Medicines Agency (EMA). (2019). Quality of biotechnological and biological medicinal products.
  4. Kőrösi, T., et al. (2015). Excipient strategies for enhancing drug solubility. International Journal of Pharmaceutics, 481(1-2), 25-40.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.